151 related articles for article (PubMed ID: 34915520)
1. Comprehensive Analysis of Bortezomib-Induced Adverse Events Using the Japanese Real-World Database.
Satoki A; Uchida M; Fujiwara M; Uesawa Y; Shimizu T
Oncology; 2022; 100(3):188-194. PubMed ID: 34915520
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Analysis of Ixazomib-Induced Adverse Events Using the Japanese Pharmacovigilance Database.
Yamaoka K; Fujiwara M; Uchida M; Uesawa Y; Muroi N; Shimizu T
Oncology; 2022; 100(7):413-418. PubMed ID: 35504255
[TBL] [Abstract][Full Text] [Related]
3. Tumor lysis syndrome associated with bortezomib: A post-hoc analysis after signal detection using the US Food and Drug Administration Adverse Event Reporting System.
Sanagawa A; Hotta Y; Kondo M; Nishikawa R; Tohkin M; Kimura K
Anticancer Drugs; 2020 Feb; 31(2):183-189. PubMed ID: 31789626
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Time-to-onset and Outcome of Lung Adverse Events With Pomalidomide from a Pharmacovigilance Study.
Kawahara Y; Murata S; Shimizu T; Uesawa Y; Uchida M
In Vivo; 2023; 37(2):955-961. PubMed ID: 36881059
[TBL] [Abstract][Full Text] [Related]
5. Adverse Event Profile of Azacitidine: Analysis by Route of Administration Using Japanese Pharmacovigilance Database.
Yamaoka K; Fujiwara M; Uchida M; Uesawa Y; Muroi N; Shimizu T
Oncology; 2023; 101(10):664-674. PubMed ID: 37279701
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Time to Onset and Outcome of Lung Adverse Events Related to Pembrolizumab Using Marketing Surveillance.
Kanbayashi Y; Kobayashi M; Anzai M; Shimizu T; Uchida M
Oncology; 2023; 101(12):817-821. PubMed ID: 37591211
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of lung toxicity with bevacizumab using the spontaneous reporting database.
Kanbayashi Y; Uchida M; Kashiwagi M; Akiba H; Shimizu T
Sci Rep; 2022 Sep; 12(1):15619. PubMed ID: 36114412
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Cardiac Adverse Events Associated with Carfilzomib Using a Japanese Real-World Database.
Nakao S; Uchida M; Satoki A; Okamoto K; Uesawa Y; Shimizu T
Oncology; 2022; 100(1):60-64. PubMed ID: 34673654
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of everolimus-induced adverse events using the Japanese real-world database.
Uchida M; Nakano K; Fujiwara M; Uesawa Y; Shimizu T
J Clin Pharm Ther; 2022 Aug; 47(8):1173-1180. PubMed ID: 35316861
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of lung adverse events with nivolumab using the spontaneous reporting system in Japan.
Kanbayashi Y; Shimizu T; Kojima A; Anzai M; Kawai R; Uchida M
Sci Rep; 2023 May; 13(1):8819. PubMed ID: 37258564
[TBL] [Abstract][Full Text] [Related]
11. Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database.
Nagai J; Ishikawa Y
PLoS One; 2021; 16(12):e0260980. PubMed ID: 34855908
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of lung adverse events with trastuzumab using the Japanese pharmacovigilance database.
Kanbayashi Y; Uchida M; Kashiwagi M; Akiba H; Shimizu T
Med Oncol; 2022 Sep; 39(12):219. PubMed ID: 36175697
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Time to Onset and Outcome of Cardiac Adverse Events Associated with Nilotinib using Post-Marketing Surveillance.
Kanbayashi Y; Kojima A; Wakabayashi H; Shimizu T; Uchida M
Oncology; 2023; 101(12):799-807. PubMed ID: 37598671
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of time-to-onset and outcome of cardiac adverse events related to pembrolizumab using post-marketing surveillance in Japanese patients.
Kanbayashi Y; Tsuchiya E; Shimizu T; Uchida M
Daru; 2024 Jun; 32(1):279-287. PubMed ID: 38671257
[TBL] [Abstract][Full Text] [Related]
15. Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database.
Sato K; Mano T; Iwata A; Toda T
J Neurooncol; 2019 Oct; 145(1):1-9. PubMed ID: 31452071
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of Time-to-onset of Interstitial Lung Disease after the Administration of Small Molecule Molecularly-targeted Drugs].
Komada F
Yakugaku Zasshi; 2018; 138(2):229-235. PubMed ID: 29386436
[TBL] [Abstract][Full Text] [Related]
17. Signal detection of human papillomavirus vaccines using the Korea Adverse Events Reporting System database, between 2005 and 2016.
Ran J; Yang JY; Lee JH; Kim HJ; Choi JY; Shin JY
Int J Clin Pharm; 2019 Oct; 41(5):1365-1372. PubMed ID: 31313003
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Cardiac Adverse Events with Nivolumab Using a Japanese Real-World Database.
Kanbayashi Y; Shimizu T; Anzai M; Kawai R; Uchida M
Clin Drug Investig; 2023 Mar; 43(3):177-184. PubMed ID: 36780109
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Cardiac Adverse Events with Ponatinib Using a Spontaneous Reporting Database.
Kanbayashi Y; Uchida M; Nakano K; Wakabayashi H; Shimizu T
Oncology; 2023; 101(6):397-405. PubMed ID: 37075717
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study.
Kondo M; Hotta Y; Yamauchi K; Sanagawa A; Komatsu H; Iida S; Kimura K
BMC Cancer; 2020 Nov; 20(1):1117. PubMed ID: 33203424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
